Laser‐Activatable In Situ Vaccine Enhances Cancer‐Immunity Cycle
Zhenyu Wang, Tingting You, Qianyi Su, Wenjia Deng, Jiabao Li, Saixiang Hu, Shengjun Shi, Zhaowei Zou, Jisheng Xiao, Xiaopin Duan
Abstract
Abstract The immune response in cancer reflects a series of carefully regulated events; however, current tumor immunotherapies typically address a single key aspect to enhance anti‐tumor immunity. In the present study, a nanoplatform (Fe 3 O 4 @IR820@CpG)‐based immunotherapy strategy that targets the multiple key steps in cancer‐immunity cycle is developed: 1) promotes the release of tumor‐derived proteins (TDPs), including tumor‐associated antigens and pro‐immunostimulatory factors), in addition to the direct killing effect, by photothermal (PTT) and photodynamic therapy (PDT); 2) captures the released TDPs and delivers them, together with CpG (a Toll‐like receptor 9 agonist) to antigen‐presenting cells (APCs) to promote antigen presentation and T cell activation; 3) enhances the tumor‐killing ability of T cells by combining with anti‐programmed death ligand 1 antibody ( α ‐PD‐L1), which collectively advances the outstanding of the anti‐tumor effects on colorectal, liver and breast cancers. The broad‐spectrum anti‐tumor activity of Fe 3 O 4 @IR820@CpG with α ‐PD‐L1 demonstrates that optimally manipulating anti‐cancer immunity not singly but as a group provides promising clinical strategies.